Tamalunas Alexander, Keller Patrick, Schott Melanie, Stadelmeier Leo Federico, Kidess Marc, Atzler Michael, Ebner Benedikt, Hennenberg Martin, Stief Christian G, Magistro Giuseppe
Department of Urology, University Hospital, LMU Munich, Munich, Germany.
Department of Urology, Asklepios Westklinikum Hamburg, Hamburg, Germany.
Prostate Cancer Prostatic Dis. 2025 Mar;28(1):153-159. doi: 10.1038/s41391-024-00831-1. Epub 2024 Apr 10.
While transurethral resection of the prostate (TURP) is the standard-of-care, Holmium laser enucleation of the prostate (HoLEP) is widely accepted as a size-independent method for surgical treatment of patients with lower urinary tract symptoms (LUTS) secondary to bladder outlet obstruction (BOO). However, in an ageing society an increasing number of patients presents with BOO due to locally advanced prostate cancer. There is currently no guidelines recommendation as to the enucleation or resection technique. Therefore, we compared intraoperative performance, postoperative outcomes, and safety for palliative (p)TURP and (p)HoLEP.
We conducted a retrospective, propensity score-matched analysis of 1373 and 2705 men who underwent TURP or HoLEP for LUTS/BOO between 2014 and 2021, respectively. Patients were matched for age, prostate size and preoperative international prostate symptom score (IPSS). Patients were stratified by technique and groups were compared for perioperative parameters, safety, and functional outcomes.
While postoperative symptoms and urodynamic parameters improved irrespective of technique, we report significantly increased resection and enucleation times for palliative indication. For corresponding efficiency parameters, we observed a two-fold higher surgical performance (g/min) for both techniques in patients without prostate cancer. While adverse events were comparable between groups, we found a two-fold higher hemoglobin drop in palliative patients.
Currently, there is no standard-of-care for patients with BOO and locally advanced prostate cancer. Our data show that both TURP and HoLEP offer adequate symptom improvement and comparable safety profiles. While HoLEP is feasible even in larger prostates, both procedures become more difficult in patients with prostate cancer. Taken together, this study covers an important gap in current literature, helping urological surgeons to make evidence-based decisions for the benefit of their patients.
经尿道前列腺切除术(TURP)是护理标准,而钬激光前列腺剜除术(HoLEP)作为一种与前列腺大小无关的手术方法,被广泛用于治疗继发于膀胱出口梗阻(BOO)的下尿路症状(LUTS)患者。然而,在老龄化社会中,因局部晚期前列腺癌导致BOO的患者数量日益增加。目前对于剜除术或切除术技术尚无指南推荐。因此,我们比较了姑息性(p)TURP和(p)HoLEP的术中表现、术后结果及安全性。
我们对2014年至2021年间分别接受TURP或HoLEP治疗LUTS/BOO的1373例和2705例男性患者进行了回顾性倾向评分匹配分析。患者在年龄、前列腺大小和术前国际前列腺症状评分(IPSS)方面进行匹配。按技术对患者进行分层,并比较各亚组的围手术期参数、安全性和功能结果。
无论采用何种技术,术后症状和尿动力学参数均有所改善,但我们发现姑息性手术的切除和剜除时间显著延长。对于相应的效率参数,我们观察到在无前列腺癌的患者中,两种技术的手术效率(克/分钟)均提高了两倍。虽然两组间不良事件相当,但我们发现姑息性手术患者的血红蛋白下降幅度高出两倍。
目前,对于BOO和局部晚期前列腺癌患者尚无护理标准。我们的数据表明,TURP和HoLEP均能充分改善症状且安全性相当。虽然HoLEP即使在较大前列腺中也可行,但两种手术在前列腺癌患者中都会变得更困难。综上所述,本研究填补了当前文献中的一个重要空白,有助于泌尿外科医生为患者做出基于证据的决策。